Synageva Biopharma Corp (GEVA) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
33 HAYDEN AVE. LEXINGTON, MA 02421 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2015 MRQ | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 446,908 | 408,733 | 218,953 | |||
| Cash and cash equivalents | 82,653 | 62,137 | 23,883 | |||
| Short-term investments | 364,255 | 346,596 | 195,070 | |||
| Receivables | 2,004 | 1,373 | 2,599 | |||
| Prepaid expense | 1,238 | 958 | ✕ | |||
| Other current assets | 3,601 | 840 | ✕ | |||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | 3,555 | ||
| Other undisclosed current assets | 4,081 | 4,819 | ||||
| Total current assets: | 457,832 | 416,723 | 225,107 | |||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 31,559 | 17,213 | 4,012 | |||
| Long-term investments and receivables | 2,000 | |||||
| Long-term investments | 2,000 | |||||
| Intangible assets, net (including goodwill) | 10,538 | 12,026 | 14,099 | |||
| Goodwill | 8,535 | 8,535 | 8,535 | |||
| Intangible assets, net (excluding goodwill) | 2,003 | 3,491 | 5,564 | |||
| Restricted cash and investments | 2,274 | 1,987 | ||||
| Other noncurrent assets | 4,274 | 1,987 | ✕ | |||
| Prepaid expense and other noncurrent assets | ✕ | ✕ | ✕ | 38 | ||
| Other undisclosed noncurrent assets | (4,274) | (1,987) | ||||
| Total noncurrent assets: | 46,371 | 31,226 | 18,149 | |||
| TOTAL ASSETS: | 504,203 | 447,949 | 243,256 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 30,428 | 16,932 | 9,550 | |||
| Employee-related liabilities | 6,093 | 3,244 | 1,862 | |||
| Accounts payable | 2,625 | 2,427 | 2,576 | |||
| Accrued liabilities | 21,710 | 11,261 | 5,112 | |||
| Other liabilities | 908 | |||||
| Deferred revenue and credits | 232 | 5,391 | ||||
| Other undisclosed current liabilities | (6,093) | (3,244) | (1,862) | |||
| Total current liabilities: | 25,243 | 13,920 | 13,079 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 5,721 | 3,828 | ||||
| Other liabilities | 5,721 | 3,828 | ||||
| Total noncurrent liabilities: | 5,721 | 3,828 | ||||
| Total liabilities: | 30,964 | 17,748 | 13,079 | |||
| Equity | ||||||
| Equity, attributable to parent | 473,239 | 430,201 | 230,177 | |||
| Common stock | 33 | 31 | 24 | |||
| Additional paid in capital | 920,333 | 684,468 | 388,936 | |||
| Accumulated other comprehensive income (loss) | (240) | (59) | 6 | |||
| Accumulated deficit | (446,887) | (254,239) | (158,789) | |||
| Total equity: | 473,239 | 430,201 | 230,177 | |||
| TOTAL LIABILITIES AND EQUITY: | 504,203 | 447,949 | 243,256 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2015 TTM | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|
| Revenues | 6,492 | 13,374 | 14,954 | ||
| Revenue, net | 6,492 | 13,374 | 15,054 | ||
| Gross profit: | 6,492 | 13,374 | 14,954 | ||
| Operating expenses | (198,625) | (109,277) | (57,975) | ||
| Other operating expense, net (Other Expenses) | (600) | ||||
| Other undisclosed operating income | 600 | ||||
| Operating loss: | (192,133) | (95,903) | (43,021) | ||
| Nonoperating expense | (4,036) | (2,327) | (310) | ||
| Investment income, nonoperating | (3,798) | (2,486) | (310) | ||
| Loss from continuing operations before equity method investments, income taxes: | (196,169) | (98,230) | (43,331) | ||
| Loss from equity method investments | (616) | ||||
| Other undisclosed income from continuing operations before income taxes | 4,677 | 2,828 | |||
| Loss from continuing operations before income taxes: | (192,108) | (95,402) | (43,331) | ||
| Income tax expense | (540) | (48) | |||
| Loss from continuing operations: | (192,648) | (95,450) | (43,331) | ||
| Loss before gain (loss) on sale of properties: | (192,648) | (95,450) | (43,331) | ||
| Net loss: | (192,648) | (95,450) | (43,331) | ||
| Other undisclosed net income attributable to parent | 382 | ||||
| Net loss available to common stockholders, diluted: | (192,648) | (95,450) | (42,949) | ||
Comprehensive Income ($ in thousands)
| 3/31/2015 TTM | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|
| Net loss: | (192,648) | (95,450) | (43,331) | ||
| Comprehensive loss: | (192,648) | (95,450) | (43,331) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (181) | (65) | 392 | ||
| Comprehensive loss, net of tax, attributable to parent: | (192,829) | (95,515) | (42,939) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.